bDMARDs Quick Reference Guide



Active ingredient


Mechanism of action

Interleukin (IL) -17A inhibitor

Molecule type

IgG monoclonal antibody (humanised)

PBS listed indications

RheumatologyAnkylosing spondylitis

Severe psoriatic arthritis

DermatologySevere chronic plaque psoriasis

Reference product (brand)


Biosimilar brands


Administration information

Mode of administration

Subcutaneous injection

Administration devices and strengths

Pre-filled pen (autoinjector) 80mg/mL

Frequency of administration

Every 4 weeks (maintenance)


Store at 2-8oC (refrigerate do not freeze).

Keep pre-filled pens in the outer carton until time of use to protect from light.

Do not shake.

Ixekizumab may be exposed to temperatures of up to 30oC for up to 5 days in total. The product must be used within these 5 days or discarded.

Standard dosing

Ankylosing spondylitis:  80mg every 4 weeks


Psoriatic arthritis: 160mg (2 x 80mg injections) at week 0 followed by 80mg every 4 weeks thereafter.


Plaque psoriasis: 160mg (2 x 80mg injections) at week 0 followed by 80 mg once every 2 weeks for 6 doses (weeks 2, 4, 6, 8, 10, 12) then 80mg every 4 weeks.


Treatment with csDMARDs (e.g., methotrexate) may be continued during treatment with ixekizumab.


Special notes

Ixekizumab has the potential to reactivate latent TB (begin TB treatment before starting).
Patients with suspected latent or active TB should be treated in consultation with an Infectious Diseases physician.

Ixekizumab may increase the risk of infection. Treatment should not be initiated in patients with clinically significant active infection until the infection resolves or is adequately treated.


New cases and exacerbations of Crohn disease and ulcerative colitis have occurred in patients being treated with ixekizumab. Patients treated with ixekizumab who have inflammatory bowel disease should be monitored closely.


Live vaccines should not be given concurrently with ixekizuamb.


Pharmaceutical benefits Scheme (PBS) listing. Available from [accessed 8/10/21]

Product information. Available from [accessed 8/10/21]

Australian Medicines Handbook 2020 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2020 July. Available from: